How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.

ABSTRACT: Adoptive immunotherapy using B-cell-targeted chimeric antigen receptor (CAR)-modified T cells to treat hematologic malignancies is transforming cancer care for patients with refractory or relapsed diseases. Recent and anticipated regulatory approval for products targeting acute lymphoblastic leukemia, lymphomas, and multiple myeloma have led to global implementation of these novel treatments. The rapidity of commercial utilization of CAR-T-cell therapy has created a largely unexplored gap in patient supportive-care approaches. Such approaches are critical in these complex patients given their high net state of immunosuppression prior to CAR-T-cell infusion coupled with unique acute and persistent insults to their immune function after CAR-T-cell infusion. In this "How I Treat" article, we

SUBMITTER: Hill JA 

PROVIDER: S-EPMC7441168 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature